GENFLOW BIOSCIENCES PLC - GENFF STOCK NEWS

Genflow Biosciences (LSE:GENF) released its half-year report for the period ending June 30, 2024. Key developments include progress in its longevity programs for MASH and Werner Syndrome, enhanced by the FDA's encouragement to proceed with pilot proof-of-concept studies using 3-D liver organoids from Werner patients. Additionally, Genflow initiated a feasibility study with Exothera S.A. for GMP-compliant production and is selecting CROs for a dog clinical trial of GF-1004.

The company received €777,281 in grants for collaborations on sarcopenia and exosome-mRNA projects and €350,000 from the Wallonia government. Financially, Genflow raised £715,000 in equity financing, bringing cash reserves to £1,139,859, despite higher administration expenses of £1,316,368. The period's operating loss was £524,259. The company remains debt-free and expects future funding to support its R&D activities.

Genflow Biosciences (LSE:GENF, OTCQB:GENFF), a leader in longevity research, announced that all resolutions at the Annual General Meeting (AGM) held on June 27, 2024, were approved.

Genflow Biosciences has announced significant strides in its pre-clinical efforts for the development of therapeutic solutions targeting age-related diseases. The company has initiated a feasibility study with Exothera S.A., a CDMO, to ensure GMP-compliant production of clinical lots. Genflow is also in the process of selecting CROs for its upcoming dog clinical trial of GF-1004. Additionally, the FDA has provided research guidance through INTERACT, advising Genflow to proceed with pilot proof-of-concept studies for GF-1002, aimed at treating Metabolic Associated Steatohepatitis (MASH). The FDA's feedback supports the continuation of toxicology and biodistribution studies, which are important for eventual clinical trials. This progress highlights Genflow's commitment to advancing its therapeutic pipeline.

Genflow Biosciences (LSE:GENF, OTCQB:GENFF), an emerging leader in longevity research, announced receiving €395,847, representing 50% of the Exofastrack research grant from the Government of Wallonia. This grant, a non-dilutive, non-reimbursable subsidy, will cover 80% of the expenses for a 3-year scientific program in collaboration with EXO Biologics. The program aims to develop exosome-based therapies targeting liver fibrosis (MASH) and Werner Syndrome. CEO Dr. Eric Leire expressed enthusiasm, emphasizing the potential for groundbreaking treatments in age-related disease prevention.

Genflow Biosciences, an emerging leader in longevity research, has announced its Annual General Meeting (AGM) scheduled for June 27, 2024, at 12 pm in London. The Notice of AGM and the 2024 Form of Proxy will soon be available on the company's website. Additionally, the company has published its Annual Report and Accounts for the year ending December 31, 2023, on the website.

Genflow Biosciences has announced the receipt of €381,434, which is 50% of a research grant from the Government of Wallonia in Belgium. This non-diluting and non-reimbursable grant will fund Genflow's sarcopenia research project over the next three years, conducted in partnership with Revatis SA. The project focuses on developing muscle progenitor cells (MPCs) loaded with Genflow's proprietary SIRT6 gene to prevent and treat sarcopenia. The remaining grant amount will be disbursed over the next two years based on submitted invoices. The goal is to enhance muscle regeneration and improve the quality of life for older adults affected by muscle loss.

Genflow Biosciences PLC disclosed a major holding by Jonathan Mark Swann, increasing the voting rights to 5.03% with 17,586,000 shares on May 9th, 2024. The London-based company received the notification on May 10th, 2024. The disclosure follows the standard TR-1 form for major holdings. The shareholder, Jonathan Mark Swann, is based in Rickmansworth, United Kingdom.

Genflow Biosciences Plc, a leader in longevity research, announces the restoration of its listing on the London Stock Exchange after publishing its FY23 Results. The Company's ordinary shares are set to be relisted, marking a significant milestone in its financial journey.

Genflow Biosciences Plc, an emerging leader in longevity research, announces its final results for the year ended 31 December 2023. The company focuses on developing therapeutic solutions for age-related diseases. Genflow is the first longevity biotechnology company listed in Europe.